Company intelligence / Profile preview
Cellemedy
Seoul, Seoul, South Koreacellemedy.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Cellemedy develops next-generation therapeutic proteins targeting cancer and other diseases, with a pipeline focused on solid tumors. Lead candidates are in preclinical development; no clinical results have been published yet.
- Therapeutic areas
- OncologyDermatologyGastroenterology
- Modalities
- Protein drugsFusion proteinsProtein drug conjugates
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Beyond the preview
Go deeper on Cellemedy.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cellemedy.